The United States is experiencing a measles resurgence at levels not seen in recent decades, driven primarily by declining vaccination coverage across communities. In response to this public health challenge, the scientific community is accelerating the development of antiviral medications and immunotherapies designed to treat infected patients and protect vulnerable populations who cannot receive traditional vaccines. These pharmaceutical interventions represent a critical strategy to combat the spread and severity of this highly contagious viral disease.

Summary auto-generated by AI from the original publisher's content. Editorial standards.